A study evaluating Velcade, melphalan and prednisone demonstrated a complete response (CR) rate of 43%, the strongest rate ever reported for a melphalan-prednisone combination therapy, Millennium said. At
In addition, new data from a phase I study showed that sunitinib malate is active and generally well-tolerated in combination with a standard chemotherapy regimen, Folfiri, in previously
Final approval of the famciclovir tablets in 125mg, 250mg and 500mg doses is expected on August 24, 2007, upon expiry of the mandatory stay of approval associated with
Based on the results, which demonstrated strong efficacy and good tolerability, the company says it will continue developing SPP635 in phase II in a special population of diabetic
Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer. The companies also confirmed that they are planning a company-sponsored phase III
The trial is designed to evaluate the therapeutic effect of its SCV-07 compound on patients with HCV. The objective of the trial is to demonstrate SCV-07’s effect on
Actos directly targets insulin resistance in type II diabetics, a condition where the body does not effectively use the insulin it produces, by improving the sensitivity to insulin
The drug will treat patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery. The French drug maker, the third
Tranzyme is developing TZP-101 as a first-in-class gastroprokinetic agent for the treatment of severe gastroparesis and post-operative ileus (POI). The data from its pilot phase IIa study was
Although response rates were similar in both arms, the trial did not meet its primary objective of demonstrating that CellCept was superior to intravenous cyclophosphamide (IVC) in inducing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.